anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a medicine registration apparatus and a program capable of omitting a part of processing based on operation record of the apparatus.SOLUTION: The medicine registration apparatus includes: a storage section; input means; execution means; and determination means. The storage section stores an operator master which holds information relevant to an operator including information on operation made by the operator. The input means is for inputting various operations on information of medicines. The execution means executes processing relevant to medicine registration corresponding to the various operations input through the input means. The determination means determines the operation record of the operator made through the input means. The execution means omits a part of the processing according to the operation record determined by the determination means.
This invention is related to a method of preparing a fermented crude extract having angiotensin converting enzyme inhibiting activity. The method comprises the following steps. A material is dried, milled, and then mixed with water in a weight ratio of 1:11 to form a mixture solution. 0.1 vol % α-amylase is used to perform hydrolysis at 95° C. for 1 hour. 0.1 vol % glucoamylase is used to perform hydrolysis at 65° C. for 4 hours. A lactic acid bacterium is added in a culture medium containing the mixture solution to perform fermentation for 24 hours. The culture medium is centrifuged to take the supernatant thereof, and the supernatant is boiled for 20 minutes. The supernatant is filtered to obtain a fermented crude extract having angiotensin converting enzyme inhibiting activity.
Background. This study examines muscle agenesis, a congenital condition that involves the absence of a muscle, focusing on the palmaris longus and plantaris muscles. The prevalence of palmaris longus agenesis varies significantly, and there is debate about whether its absence results in functional disability or is a predictor of injuries. Muscle injuries account for one-third of sports injuries and more than 30% of all musculoskeletal system injuries. The presence or absence of certain muscles can influence the body's biomechanics and, therefore, susceptibility to injuries, as muscles play a crucial role in generating force and coordination, hence movement. The absence of certain muscles may require other muscles to compensate, which could affect the efficiency and performance capacity in certain body areas. However, in many cases, the absence of a muscle may not have a significant effect on performance, as other muscles can adapt to perform its function. This study seeks to provide clarity in this area of research due to the existing controversy in the scientific literature.

Objectives. To determine if muscle agenesis influences the development of injuries and its impact on strength and performance.

Material and methods. An observational analytical cross-sectional study was conducted with 132 subjects divided into one group of 66 subjects with muscle agenesis and another group of 66 subjects without muscle agenesis. The primary variable is the presence of upper and lower limb injuries measured using the Nordic and CMDQ questionnaires, and the secondary variable is upper limb strength measured with a dynamometer in palmar flexion and hand grip tests; and lower limb strength measured with a dynamometer in plantar flexion and vertical jump tests. The measurements were taken over 1 hour and 30 minutes during two days, with a 48-hour interval between the measurements of the upper and lower limbs.
The invention belongs to the field of drug analysis, relates to a method for screening an active component in a traditional Chinese medicine, and specifically, relates to a method for screening a traditional Chinese medicine active component with a function of hexokinase inhibition effects. Based on hexokinase catalytic reaction adopting adenosine triphosphate (ATP) as a substrate, the method can screen out a traditional Chinese medicine active component with a function of hexokinase inhibition effects through quantitative analysis processes on ATP and product ATP. The method is rapid, simple, economic and effective. Compared with a cell test method, the method reduces an extract use amount, saves biochemical reagents, and shortens a screening period. Therefore, the method has great importance for screening and research of traditional Chinese medicine active components. In the invention, all experiment parameters of an improved liquid chromatography-mass spectrometry (LC-MS) method have good reference values for mass spectrometry technology-based determination of other biomolecules with similar properties.
The participants consume the polyphenol-rich drink. After 3 hours they consume a standard meal to evaluate whether the metabolic response may be influenced by polyphenols.
Registered participants will undergo a clinical assessment to determine whether they have high or low levels of skin ageing. The study will recruit 5 subjects with low levels of skin ageing and 5 subjects with high levels of skin ageing. Recruited patients will undergo skin punch biopsies, blood sampling and collection of lifestyle data.
Titration of morphine by Patient Controlled Analgesy. The opioid titration will be performed by the patient using PCA (Vygon Freedom 5) according to the principle of self with a refractory period of 5 minutes.
The recommended adult dosage for the treatment of acute and recurrent diabetic gastroparesis is 10 mg four times daily for 2 to 8 weeks, depending on symptomatic response. Avoid Reglan treatment for greater than 12 weeks [see Warnings and Precautions (5.1)]. Administer the dosage thirty minutes before each meal and at bedtime. The maximum recommended daily dosage is 40 mg. 

Table 2 displays the recommended daily dosage and maximum daily dosage for adults and dosage adjustments for patients with moderate or severe hepatic impairment (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute, in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with strong CYP2D6 inhibitors.

If patients with diabetic gastroparesis have severe nausea or vomiting and are unable to take oral Reglan tablets, consider starting therapy with metoclopramide injection given intramuscularly or intravenously for up to 10 days (see the prescribing information for metoclopramide injection). After patients are able to take oral therapy, switch to Reglan tablets. 

     Table 2. Recommended Reglan Tablet Dosage in Patients with Acute and Recurrent Diabetic Gastroparesis

     1 Elderly patients may be more sensitive to the therapeutic or adverse effects of Reglan; therefore, consider a lower dosage of 5 mg four times daily with titration to the recommended adult dosage of 10 mg four times daily based upon response and tolerability.
<P>PROBLEM TO BE SOLVED: To provide a method for stably preserve a protein-containing composition, especially an antibiotic preparation for a long period and a vessel for the stable preservation.  <P>SOLUTION: The protein-containing composition can be stabilized by storing the protein-containing composition under a light-shielded condition. A light-shielding vessel can be used for the preservation under the light-shielded condition. The amount of a stabilizer added to the protein-containing composition can be decreased by this method. The combined use of the method of the present invention and the addition of a stabilizer is effective for suppressing coagulation, denaturation, decomposition and formation of insoluble foreign materials.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention discloses two shRNAs interfering with human IL-6 gene expression, which are shown as SEQ ID NO 1 and SEQ ID NO 2. The invention also discloses a lentivirus expression vector which comprises shRNA for interfering the expression of the human IL-6 gene and a nucleotide segment which is shown as SEQ ID NO. 4 and used for coding the chimeric antigen receptor. The invention also discloses a CD19-CAR-T cell for interfering the expression of the human IL-6 gene, which is a T lymphocyte containing a lentivirus expression vector or a T lymphocyte integrating shRNA for interfering the expression of the human IL-6 gene in a chromosome and encoding a nucleotide fragment of a chimeric antigen receptor. IL-6shRNA is introduced into the CAR-T cell, the shRNA of IL-6 is co-expressed while CAR is expressed, and the release of IL-6 is inhibited from the source through a gene silencing technology, so that the influence of CRS is reduced, and the safety of CAR-T treatment is improved. It can be expected that the compound has important application in preparing medicaments for preventing, treating and assisting in treating malignant tumors.
Patient receives treatment at baseline and week 4 visit. The first time extension criteria are met the follow-up interval will be increased by 4 weeks. Each time the extension criteria is met the interval will be extended by 2 weeks to a maximum of 16 weeks. If a patient is being followed at an 8 week interval but fails to meet extension criteria at a particular visit, treatment will be administered as usual and the follow up interval will be reduced to 4 weeks. If patient is being followed at 10-16 week interval but fails to meet extension criteria at a particular visit, treatment will be administered but the follow-up interval will be reduced by 2 week increments.
PURPOSE: To prepare a multicomponent mixed capsule having a specified length from pulverizable glass having a specified wall thickness by introducing a liquid pad into an ampul and thereafter spraying a powdery alloy onto the liquid pad which is present at a lower part. CONSTITUTION: A multicomponent mixed capsule made of glass contains filled powders and liquid in a plastic pad. In this case, a liquid pad 3 is introduced in an ampul having a narrowed part 5 at a surrounding wall 1 by opening upward in the filing time for preparation. Thereafter, a powdery component 4 is sprayed on the liquid pad 3 which is present at a lower part. The liquid is mercury, and the powdery alloy is one suitable for preparation of dental amalgam. Furthermore, nitrogen is filled into an inside of a flat-bottom glass body as one preparation procedure. Thereby, a capsule having a specified length can be prepared from pulverizable glass having a specified wall thickness.
INTRODUCTION: Sexually transmitted infections (STIs) are a significant public health concern globally, particularly affecting young women. Early diagnosis and treatment are essential to reducing or stopping the continuous spread of infections and the development of associated complications. Syndromic management, which is commonly used for STIs, presents several barriers, particularly for young women. This protocol is for a study that aims to understand young women's preferences for a self-sampling intervention for STI diagnosis by using a discrete choice experiment (DCE). The DCE will be conducted among young women residing in underserved urban communities in eThekwini Metropolitan Municipality in KwaZulu-Natal, South Africa.
METHODS AND ANALYSIS: The following attributes of a self-sampling intervention were identified through a Nominal Group Technique: accessibility, education, confidentiality, self-sampling method, youth-friendliness and cost. A pilot study involving 20 participants was conducted to refine the DCE questionnaire. A total of 196 young women from underserved communities will be recruited. The participants will be sampled from communities, stratified by settlement type and socioeconomic status. Data will be analysed using the multinomial logit model and mixed logit model to assess preferences and heterogeneity.
ETHICS AND DISSEMINATION: The study was approved by the Faculty of Health Sciences Research Ethics Committee of the University of Pretoria. The study findings have the potential to inform policies for STI treatment and management to align healthcare services with user preferences. This can improve STI healthcare access for young women in underserved communities. Ethical approval was obtained, and results will be disseminated through peer-reviewed journals and health conferences.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine also can be used for treating vast purulent wounds of soft tissues. That is ensured by exposure of a wound surface to high-energy semiconductor lasing after opening of a suppurative focus and detritus evacuation. Then the wound is irrigated with an antiseptic and exposed to defocused CO2-laser beam of power 20 Wt, light spot diametre 1 cm in the continuous mode. On the 2 day after the beginning of treatment, provided no secondary necroses observed, a session of photodynamic therapy follows. Herewith, the wound surface is coated with Photoditazine modified gel of methyl hydroxyethyl cellulose esters containing 0.5-1.5% dimethylglucamine salt of chlorine E6. Before applications, gel is mixed with 25% aqueous polyethylene oxide in the volumetric ratio gel: polyethylene oxide 10:2-3. Then it is exposed to semiconductor lasing of wave length 0.660.03 mcm, power density 0.5 to 1.0 Wt/cm2 and energy density 20 J/cm2. If detecting the signs secondary necrosis, before photodynamic therapy, the wound is processed with defocused CO2-laser beam one more time. Another session of photodynamic therapy is required, when on the 2nd day after photodynamic therapy, perifocal inflammatory manifestations remain in the wound. ^ EFFECT: method allows preventing development of secondary necroses and growth of residual microflora in the purulent wound, stimulating reparative processes, reducing length of treatment of vast purulent wounds and pyoinflammatory diseases of soft tissues. ^ 3 cl, 2 ex
ABSTRACTThis study investigates factors influencing lexical access in language production across modalities (signed and oral). Data from deaf and hearing signers were reanalyzed (Baus and Costa, 2015, On the temporal dynamics of sign production: An ERP study in Catalan Sign Language (LSC). Brain Research, 1609(1), 40-53. https://doi.org/10.1016/j.brainres.2015.03.013; Gimeno-Martínez and Baus, 2022, Iconicity in sign language production: Task matters. Neuropsychologia, 167, 108166. https://doi.org/10.1016/j.neuropsychologia.2022.108166) testing the influence of psycholinguistic variables and ERP mean amplitudes on signing and naming latencies. Deaf signers' signing latencies were influenced by sign iconicity in the picture signing task, and by spoken psycholinguistic variables in the word-to-sign translation task. Additionally, ERP amplitudes before response influenced signing but not translation latencies. Hearing signers' latencies, both signing and naming, were influenced by sign iconicity and word frequency, with early ERP amplitudes predicting only naming latencies. These findings highlight general and modality-specific determinants of lexical access in language production.
Membranous nephropathy (MN) is a common cause of nephrotic syndrome in middle-aged and older adults. MN etiology is mainly primary or idiopathic; however, it may also be secondary to infections, drugs, neoplasms, and autoimmune diseases. We present the case of a 52-year-old Japanese man with coexisting nephrotic MN and immune thrombocytopenic purpura (ITP). Renal biopsy revealed glomerular basement membrane thickening with immunoglobulin (Ig) G and complement component 3 deposition. Glomerular IgG subclass analysis revealed predominant IgG4 deposition with weak IgG1 and IgG2 deposition. IgG3 and phospholipase A2 receptor deposits were negative. Upper endoscopy revealed no ulcers, but histological examination demonstrated Helicobacter pylori infection in the gastric mucosa with elevated IgG antibodies. After gastric Helicobacter pylori eradication, the nephrotic-range proteinuria and thrombocytopenia of the patient were markedly improved without initiation of immunosuppressive treatment. Therefore, clinicians should consider the possibility of Helicobacter pylori infection in patients with coexisting MN and ITP. Further studies are required to demonstrate the associated pathophysiological aspects.
Participate will join a four-day integrated health education and adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 15 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
BACKGROUND: The pathogenesis of cardiac arrhythmias is multifaceted, encompassing genetic, environmental, hemodynamic, and various causative factors. Emerging evidence underscores a plausible connection between gut flora, serum metabolites, and specific types of arrhythmias. Recognizing the role of host genetics in shaping the microbiota, we employed two-sample Mendelian randomization analyses to investigate potential causal associations between gut flora, serum metabolites, and distinct arrhythmias.
METHODS: Mendelian randomization methods were deployed to ascertain causal relationships between 211 gut flora, 575 serum metabolites, and various types of arrhythmias. To ensure the reliability of the findings, five complementary Mendelian randomization methods, including inverse variance weighting methods, were employed. The robustness of the results was scrutinized through a battery of sensitivity analyses, incorporating the Cochran Q test, leave-one-out test, and MR-Egger intercept analysis.
RESULTS: Eighteen gut flora and twenty-six serum metabolites demonstrated associations with the risk of developing atrial fibrillation. Moreover, ten gut flora and fifty-two serum metabolites were linked to the risk of developing supraventricular tachycardia, while eight gut flora and twenty-five serum metabolites were associated with the risk of developing tachycardia. Additionally, six gut flora and twenty-one serum metabolites exhibited associations with the risk of developing bradycardia.
CONCLUSION: This study revealed the potential causal relationship that may exist between gut flora, serum metabolites and different cardiac arrhythmias and highlights the need for further exploration. This study provides new perspectives to enhance diagnostic and therapeutic strategies in the field of cardiac arrhythmias.
This is a single institution, prospective cohort study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an early measure of response in patients with melanoma. This study is a companion imaging study to the "LIMIT Melanoma Trial". Patients with melanoma who are candidates for the LIMIT Melanoma treatment trial and are at least 18 years of age may be eligible. All participants will be receiving care at the clinical practices of the University of Pennsylvania. Patients will be approached about study participation regardless of race or ethnic background. We anticipate enrolling up to 20 evaluable participants with melanoma who meet eligibility requirements for this study. An evaluable patient has completed Baseline and at the post-Treatment Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans. Accrual is estimated to occur over approximately 3 years.

After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a BaselineZirconium Zr 89 Crefmirlimab Berdoxa PET/CT scan prior to starting immunotherapy + HCQ therapy. For the Baseline study, subjects will be injected with Zirconium Zr 89 Crefmirlimab Berdoxa up to 8 days prior to starting therapy (Day -8 to 0), and will undergo PET/CT imaging 24 ± 4 hours post injection, and prior to therapy administration. Subjects will then undergo a Post-Treatment Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scan at day 14 (± 4 days) post therapy, which will require administration of Zirconium Zr 89 Crefmirlimab Berdoxa on the day prior to the scan. Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans will be acquired with an interval of ≥ 10 days between scans, to ensure that the signal from the previous injection of Zirconium Zr 89 Crefmirlimab Berdoxa has decayed.
Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous or intra-arterial administration..

Select mode of therapy, frequency of treatment, formulation, fill volume, duration of dwell, and length of dialysis based on the patient’s clinical condition, fluid, electrolyte and specific needs. The fill volume depends on body size, usually from 2.0 to 2.5 liters per 1.73m2 for adults. 

DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD). Refer to directions accompanying ancillary equipment for CAPD and APD system preparation. 

Product Selection

To avoid the risk of severe dehydration and hypovolemia and to minimize the loss of protein, it is advisable to select the peritoneal dialysis solution with the lowest level of osmolarity consistent with the fluid removal requirements for that exchange. As the patient’s body weight becomes closer to the ideal dry weight, lowering the dextrose concentration of DIANEAL solution is recommended. DIANEAL 4.25% dextrose-containing solution has the highest osmolarity of the DIANEAL solutions and using it for all exchanges may cause dehydration [see Dosage Forms and Strengths (3)].
This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
Participants in the control group continued their usual habitual diet for 8 weeks. No specific dietary advice or educations were provided throughout the entire trial.
Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, allergic diseases or asthma, containing a  Diospyros blancoi  A. DC. extract as an active ingredient. More specifically, a  Diospyros blancoi  A. DC. extract inhibits the generation of NO and PGE2 which rapidly increases due to the induction of inflammation, which suppresses the transfer of NF-κB into a nucleus, thereby inhibiting the expression of iNOS and COX-2 and remarkably reducing the amounts of TNF-α, IL-1β, IL-4 and IL-13. In addition, the  Diospyros blancoi  A. DC. extract inhibits eosinophilia in bronchoalveolar lavage fluid in the ovalbumin-induced asthma mouse model and inhibits the secretion of immunoglobulins and chemokines in bronchoalveolar lavage fluid and blood. Therefore, the  Diospyros blancoi  A. DC. extract can be beneficially used as an active ingredient for compositions used for preventing or treating inflammatory diseases, allergic diseases or asthma.